Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

47 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Impact of Donor Type in Patients with AML Given Allogeneic Hematopoietic Cell Transplantation After Low-Dose TBI-Based Regimen.
Baron F, Labopin M, Ruggeri A, Cornelissen JJ, Meijer E, Sengeloev H, Niederwieser D, De Groot MR, Schouten HC, Milpied N, Blaise D, Savani BN, Gluckman E, Mohty M, Nagler A. Baron F, et al. Among authors: de groot mr. Clin Cancer Res. 2018 Jun 15;24(12):2794-2803. doi: 10.1158/1078-0432.CCR-17-3622. Epub 2018 Mar 19. Clin Cancer Res. 2018. PMID: 29555662 Free article.
Short-term efficacy and safety of antithymocyte globulin treatment in elderly patients with acquired aplastic anaemia.
Tjon JM, de Groot MR, Sypkens Smit SMA, de Wreede LC, Snijders TJF, Koene HR, Meijer E, Raaijmakers MHG, Schaap M, Raymakers R, Zeerleder SS, Halkes CJM. Tjon JM, et al. Among authors: de groot mr, de wreede lc. Br J Haematol. 2018 Feb;180(3):459-462. doi: 10.1111/bjh.14372. Epub 2016 Oct 7. Br J Haematol. 2018. PMID: 27714765 Free article. No abstract available.
Anti-thymocyte globulin for graft-versus-host disease prophylaxis in patients with intermediate- or high-risk acute myeloid leukaemia undergoing reduced-intensity conditioning allogeneic stem cell transplantation in first complete remission - a survey on behalf of the Acute Leukaemia Working Party of the European Society for Blood and Marrow Transplantation.
Ofran Y, Beohou E, Labopin M, Blaise D, Cornelissen JJ, de Groot MR, Socié G, Huynh A, Maertens J, Baron F, Mohty M, Nagler A. Ofran Y, et al. Among authors: de groot mr. Br J Haematol. 2019 Feb;184(4):643-646. doi: 10.1111/bjh.15131. Epub 2018 Feb 21. Br J Haematol. 2019. PMID: 29468648 Free article. Clinical Trial. No abstract available.
EBMT prospective observational study on allogeneic hematopoietic stem cell transplantation in T-prolymphocytic leukemia (T-PLL).
Wiktor-Jedrzejczak W, Drozd-Sokolowska J, Eikema DJ, Hoek J, Potter M, Wulf G, Sellner L, Ljungman P, Chevallier P, Volin L, Koc Y, Martin S, Bunjes D, Rovira M, Itälä-Remes M, Foá R, Deconinck E, Gedde-Dahl T, Cornelissen J, Collin M, Brecht A, Patel A, de Groot M, Reményi P, Nagler A, Finke J, Turlure P, Iacobelli S, van Biezen A, Schetelig J, Kröger N, Dreger P. Wiktor-Jedrzejczak W, et al. Bone Marrow Transplant. 2019 Sep;54(9):1391-1398. doi: 10.1038/s41409-019-0448-x. Epub 2019 Jan 21. Bone Marrow Transplant. 2019. PMID: 30664723 Clinical Trial.
Exploratory Study of Predicted Indirectly ReCognizable HLA Epitopes in Mismatched Hematopoietic Cell Transplantations.
Geneugelijk K, Thus KA, van Deutekom HWM, Calis JJA, Borst E, Keşmir C, Oudshoorn M, van der Holt B, Meijer E, Zeerleder S, de Groot MR, von dem Borne PA, Schaap N, Cornelissen J, Kuball J, Spierings E. Geneugelijk K, et al. Among authors: de groot mr. Front Immunol. 2019 Apr 24;10:880. doi: 10.3389/fimmu.2019.00880. eCollection 2019. Front Immunol. 2019. PMID: 31068946 Free PMC article.
Stem cell transplantation from a haploidentical donor versus a genoidentical sister for adult male patients with acute myelogenous leukemia in first remission: A retrospective study from the acute leukemia working party of the European Society for Blood and Marrow Transplantation.
Gorin NC, Labopin M, Blaise D, de Groot M, Socié G, Bourhis JH, Ciceri F, Polge E, Nagler A, Mohty M. Gorin NC, et al. Cancer. 2020 Mar 1;126(5):1004-1015. doi: 10.1002/cncr.32629. Epub 2019 Nov 27. Cancer. 2020. PMID: 31774557 Free article.
Low relapse risk in poor risk AML after conditioning with 10-day decitabine, fludarabine and 2 Gray TBI prior to allogeneic hematopoietic cell transplantation.
Cruijsen M, Hilberink JR, van der Velden WJFM, Jansen JH, Bär B, Schaap NPM, de Haan A, Mulder AB, de Groot MR, Baron F, Vellenga E, Blijlevens NNM, Huls G. Cruijsen M, et al. Among authors: de groot mr. Bone Marrow Transplant. 2021 Aug;56(8):1964-1970. doi: 10.1038/s41409-021-01272-3. Epub 2021 Apr 6. Bone Marrow Transplant. 2021. PMID: 33824442 Free article. Clinical Trial.
Posttransplant cyclophosphamide for prevention of graft-versus-host disease: results of the prospective randomized HOVON-96 trial.
Broers AEC, de Jong CN, Bakunina K, Hazenberg MD, van Marwijk Kooy M, de Groot MR, van Gelder M, Kuball J, van der Holt B, Meijer E, Cornelissen JJ. Broers AEC, et al. Among authors: de groot mr. Blood Adv. 2022 Jun 14;6(11):3378-3385. doi: 10.1182/bloodadvances.2021005847. Blood Adv. 2022. PMID: 35143644 Free PMC article. Clinical Trial.
Improved Outcome of Allogeneic Transplantation in Older Patients Treated for Myeloid Malignancies Using Post-Transplantation Cyclophosphamide and Reduced Duration of Immune Suppression.
Morsink LM, Hazenberg CLE, Choi G, de Groot MR, Biswana A, Bellido M, Kooistra HAM, Bungener LB, Meijer K, Mulder AB, Huls G. Morsink LM, et al. Among authors: de groot mr. Transplant Cell Ther. 2024 May 11:S2666-6367(24)00406-8. doi: 10.1016/j.jtct.2024.05.009. Online ahead of print. Transplant Cell Ther. 2024. PMID: 38740138 Free article.
47 results